{"id":65216,"date":"2026-05-13T23:21:24","date_gmt":"2026-05-13T15:21:24","guid":{"rendered":"https:\/\/flcube.com\/?p=65216"},"modified":"2026-05-13T23:21:25","modified_gmt":"2026-05-13T15:21:25","slug":"porton-advanced-solutions-and-dark-horse-consulting-forge-strategic-alliance-to-accelerate-global-cell-and-gene-therapy-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65216","title":{"rendered":"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development"},"content":{"rendered":"\n<p><strong>Porton Advanced Solutions<\/strong> and <strong>Dark Horse Consulting Group (&#8220;DHCG&#8221;)<\/strong> announced on May 12, 2026, the signing of a <strong>Memorandum of Understanding (MOU)<\/strong> to establish a <strong>strategic collaboration<\/strong> aimed at accelerating the <strong>development and clinical translation of cell and gene therapies globally<\/strong>, with particular focus on enabling <strong>Investigator-Initiated Trials (IITs) in China<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Porton Advanced Solutions + Dark Horse Consulting Group (DHCG)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Memorandum of Understanding (MOU)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>May 12, 2026<\/td><\/tr><tr><td><strong>Primary Focus<\/strong><\/td><td>Cell and gene therapy development acceleration<\/td><\/tr><tr><td><strong>Geographic Emphasis<\/strong><\/td><td>Global reach with China IIT specialization<\/td><\/tr><tr><td><strong>Service Integration<\/strong><\/td><td>End-to-end development and manufacturing pathway<\/td><\/tr><tr><td><strong>Target Clients<\/strong><\/td><td>Biotech companies and academic institutions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-integrated-capabilities-matrix\">Integrated Capabilities Matrix<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dark-horse-consulting-group-expertise\">Dark Horse Consulting Group Expertise<\/h3>\n\n\n\n<p>DHCG contributes comprehensive <strong>regulatory and development consulting capabilities<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory strategy<\/strong>: Global regulatory submissions and agency interactions<\/li>\n\n\n\n<li><strong>CMC development<\/strong>: Chemistry, manufacturing, and controls optimization<\/li>\n\n\n\n<li><strong>Nonclinical studies<\/strong>: Preclinical safety and efficacy program design<\/li>\n\n\n\n<li><strong>Clinical development<\/strong>: Trial design, execution, and data management<\/li>\n\n\n\n<li><strong>Quality &amp; compliance<\/strong>: GMP\/GLP compliance and quality systems<\/li>\n\n\n\n<li><strong>Supply chain<\/strong>: Logistics and distribution strategy<\/li>\n\n\n\n<li><strong>Commercial launch<\/strong>: Market access and commercialization planning<\/li>\n\n\n\n<li><strong>Business analytics<\/strong>: Portfolio prioritization and investment analysis<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-porton-advanced-manufacturing-infrastructure\">Porton Advanced Manufacturing Infrastructure<\/h3>\n\n\n\n<p>Porton Advanced Solutions provides <strong>end-to-end GMP manufacturing capabilities<\/strong> across multiple modalities:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Modality<\/th><th>Capabilities<\/th><th>Scale<\/th><\/tr><\/thead><tbody><tr><td><strong>Viral Vectors<\/strong><\/td><td>Lentiviral vectors, AAV<\/td><td>Clinical to commercial<\/td><\/tr><tr><td><strong>Nucleic Acid Therapies<\/strong><\/td><td>mRNA\/LNP, plasmids<\/td><td>Multi-product facilities<\/td><\/tr><tr><td><strong>Engineered Cell Therapies<\/strong><\/td><td>CAR-T, CAR-NK, iPSC-derived products<\/td><td>Automated and manual platforms<\/td><\/tr><tr><td><strong>Quality Systems<\/strong><\/td><td>Full GMP compliance<\/td><td>International standards<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-value-proposition\">Strategic Value Proposition<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-accelerated-clinical-pathway\">Accelerated Clinical Pathway<\/h3>\n\n\n\n<p>The integrated partnership offers clients a <strong>streamlined route to clinical-stage manufacturing<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced timeline<\/strong>: Elimination of vendor coordination delays through single-point integration<\/li>\n\n\n\n<li><strong>Cost efficiency<\/strong>: Optimized resource allocation and reduced overhead costs<\/li>\n\n\n\n<li><strong>Risk mitigation<\/strong>: Seamless technology transfer and process continuity<\/li>\n\n\n\n<li><strong>Regulatory harmonization<\/strong>: Coordinated global regulatory strategy with local expertise<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-china-iit-specialization\">China IIT Specialization<\/h3>\n\n\n\n<p>Particular emphasis on <strong>enabling Investigator-Initiated Trials in China<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Local regulatory expertise<\/strong>: NMPA-compliant development pathways<\/li>\n\n\n\n<li><strong>Academic collaboration<\/strong>: Support for university and hospital-based research programs<\/li>\n\n\n\n<li><strong>Manufacturing access<\/strong>: GMP production for early-stage clinical trials<\/li>\n\n\n\n<li><strong>Market bridge<\/strong>: Pathway from Chinese IITs to global clinical development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-industry-impact\">Market Context &amp; Industry Impact<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cell-and-gene-therapy-landscape\">Cell and Gene Therapy Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market growth<\/strong>: Global cell and gene therapy market projected to reach <strong>$40+ billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing bottleneck<\/strong>: Limited GMP capacity creating significant development delays<\/li>\n\n\n\n<li><strong>China emergence<\/strong>: Rapidly growing Chinese CGT sector requiring specialized support infrastructure<\/li>\n\n\n\n<li><strong>IIT importance<\/strong>: Investigator-initiated trials serving as critical proof-of-concept for novel therapies<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Integrated model<\/strong>: Unique combination of consulting and manufacturing under coordinated framework<\/li>\n\n\n\n<li><strong>Modality breadth<\/strong>: Comprehensive coverage across viral vectors, nucleic acids, and cell therapies<\/li>\n\n\n\n<li><strong>Global-local balance<\/strong>: International regulatory expertise combined with China-specific capabilities<\/li>\n\n\n\n<li><strong>Academic focus<\/strong>: Specialized support for non-commercial research translating to clinical applications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-emerging-biotechs\">For Emerging Biotechs<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>De-risked development<\/strong>: Access to established infrastructure reduces capital requirements<\/li>\n\n\n\n<li><strong>Expert guidance<\/strong>: Regulatory and technical expertise accelerates development timelines<\/li>\n\n\n\n<li><strong>Global strategy<\/strong>: Support for both local Chinese development and international expansion<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-academic-institutions\">For Academic Institutions<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Translation enablement<\/strong>: Bridge between basic research and clinical application<\/li>\n\n\n\n<li><strong>GMP access<\/strong>: Manufacturing capability previously unavailable to academic researchers<\/li>\n\n\n\n<li><strong>Regulatory navigation<\/strong>: Expertise in complex regulatory requirements for first-in-human studies<\/li>\n<\/ul>\n\n\n\n<p>The partnership represents a <strong>strategic response<\/strong> to the growing complexity and capital intensity of cell and gene therapy development, offering a comprehensive solution that addresses both technical and regulatory challenges across global markets.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership implementation and market impact. Actual outcomes may differ due to risks including regulatory changes, competitive dynamics, and implementation challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Porton Advanced Solutions and Dark Horse Consulting Group (&#8220;DHCG&#8221;) announced on May 12, 2026, the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[4260],"class_list":["post-65216","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-porton-advanced-solutions"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Porton Advanced Solutions and Dark Horse Consulting Group (&quot;DHCG&quot;) announced on May 12, 2026, the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally, with particular focus on enabling Investigator-Initiated Trials (IITs) in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development\" \/>\n<meta property=\"og:description\" content=\"Porton Advanced Solutions and Dark Horse Consulting Group (&quot;DHCG&quot;) announced on May 12, 2026, the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally, with particular focus on enabling Investigator-Initiated Trials (IITs) in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T15:21:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T15:21:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development\",\"datePublished\":\"2026-05-13T15:21:24+00:00\",\"dateModified\":\"2026-05-13T15:21:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65216\"},\"wordCount\":573,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Porton Advanced Solutions\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65216#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65216\",\"name\":\"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T15:21:24+00:00\",\"dateModified\":\"2026-05-13T15:21:25+00:00\",\"description\":\"Porton Advanced Solutions and Dark Horse Consulting Group (\\\"DHCG\\\") announced on May 12, 2026, the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally, with particular focus on enabling Investigator-Initiated Trials (IITs) in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65216\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development - Insight, China&#039;s Pharmaceutical Industry","description":"Porton Advanced Solutions and Dark Horse Consulting Group (\"DHCG\") announced on May 12, 2026, the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally, with particular focus on enabling Investigator-Initiated Trials (IITs) in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65216","og_locale":"en_US","og_type":"article","og_title":"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development","og_description":"Porton Advanced Solutions and Dark Horse Consulting Group (\"DHCG\") announced on May 12, 2026, the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally, with particular focus on enabling Investigator-Initiated Trials (IITs) in China.","og_url":"https:\/\/flcube.com\/?p=65216","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T15:21:24+00:00","article_modified_time":"2026-05-13T15:21:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development","datePublished":"2026-05-13T15:21:24+00:00","dateModified":"2026-05-13T15:21:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65216"},"wordCount":573,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Porton Advanced Solutions"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65216#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65216","url":"https:\/\/flcube.com\/?p=65216","name":"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T15:21:24+00:00","dateModified":"2026-05-13T15:21:25+00:00","description":"Porton Advanced Solutions and Dark Horse Consulting Group (\"DHCG\") announced on May 12, 2026, the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally, with particular focus on enabling Investigator-Initiated Trials (IITs) in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65216"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65216"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65216\/revisions"}],"predecessor-version":[{"id":65217,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65216\/revisions\/65217"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}